Nivolumab recommended for treatment of melanoma with lymph node involvement or metastatic disease in adults

Clinical evidence shows that adjuvant nivolumab increases how long people live without the cancer coming back compared with adjuvant ipilimumab.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in